1
|
Sphingolipids in Type 1 Diabetes: Focus on Beta-Cells. Cells 2020; 9:cells9081835. [PMID: 32759843 PMCID: PMC7465050 DOI: 10.3390/cells9081835] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 08/01/2020] [Accepted: 08/03/2020] [Indexed: 12/28/2022] Open
Abstract
Type 1 diabetes (T1DM) is a chronic autoimmune disease, with a strong genetic background, leading to a gradual loss of pancreatic beta-cells, which secrete insulin and control glucose homeostasis. Patients with T1DM require life-long substitution with insulin and are at high risk for development of severe secondary complications. The incidence of T1DM has been continuously growing in the last decades, indicating an important contribution of environmental factors. Accumulating data indicates that sphingolipids may be crucially involved in T1DM development. The serum lipidome of T1DM patients is characterized by significantly altered sphingolipid composition compared to nondiabetic, healthy probands. Recently, several polymorphisms in the genes encoding the enzymatic machinery for sphingolipid production have been identified in T1DM individuals. Evidence gained from studies in rodent islets and beta-cells exposed to cytokines indicates dysregulation of the sphingolipid biosynthetic pathway and impaired function of several sphingolipids. Moreover, a number of glycosphingolipids have been suggested to act as beta-cell autoantigens. Studies in animal models of autoimmune diabetes, such as the Non Obese Diabetic (NOD) mouse and the LEW.1AR1-iddm (IDDM) rat, indicate a crucial role of sphingolipids in immune cell trafficking, islet infiltration and diabetes development. In this review, the up-to-date status on the findings about sphingolipids in T1DM will be provided, the under-investigated research areas will be identified and perspectives for future studies will be given.
Collapse
|
2
|
Abstract
Recent technical advances have re-invigorated the study of sphingolipid metabolism in general, and helped to highlight the varied and important roles that sphingolipids play in pancreatic β-cells. Sphingolipid metabolites such as ceramide, glycosphingolipids, sphingosine 1-phosphate and gangliosides modulate many β-cell signaling pathways and processes implicated in β-cell diabetic disease such as apoptosis, β-cell cytokine secretion, ER-to-golgi vesicular trafficking, islet autoimmunity and insulin gene expression. They are particularly relevant to lipotoxicity. Moreover, the de novo synthesis of sphingolipids occurs on many subcellular membranes, in parallel to secretory vesicle formation, traffic and granule maturation events. Indeed, the composition of the plasma membrane, determined by the activity of neutral sphingomyelinases, affects β-cell excitability and potentially insulin exocytosis while another glycosphingolipid, sulfatide, determines the stability of insulin crystals in granules. Most importantly, sphingolipid metabolism on internal membranes is also strongly implicated in regulating β-cell apoptosis.
Collapse
Affiliation(s)
- Ebru Boslem
- Diabetes and Obesity Program; Garvan Institute of Medical Research; Darlinghurst, NSW Australia
- St Vincent’s Clinical School; Faculty of Medicine; University of New South Wales; Sydney, NSW Australia
| | - Peter J. Meikle
- Baker IDI Heart and Diabetes Institute; Melbourne, VIC Australia
| | - Trevor J. Biden
- Diabetes and Obesity Program; Garvan Institute of Medical Research; Darlinghurst, NSW Australia
- St Vincent’s Clinical School; Faculty of Medicine; University of New South Wales; Sydney, NSW Australia
- Correspondence to: Trevor J. Biden,
| |
Collapse
|
3
|
Pietropaolo M, Yu S, Libman IM, Pietropaolo SL, Riley K, LaPorte RE, Drash AL, Mazumdar S, Trucco M, Becker DJ. Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies. Pediatr Diabetes 2005; 6:184-92. [PMID: 16390386 DOI: 10.1111/j.1399-543x.2005.00127.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
The discovery of islet cell antibodies (ICAs) was the prelude to the understanding that type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease. The issue regarding whether or not the measurement of ICAs should be completely replaced by biochemical markers detecting islet autoantibodies (AAs) for the prediction of T1DM has been the subject of endless international debates. In light of this controversy, we assessed the current role of ICAs as a predictive marker for T1DM progression. We examined a cohort of 1484 first-degree relatives (FDRs) of T1DM probands from the Children's Hospital of Pittsburgh Registry. These relatives were consecutively enrolled between 1979 through 1984 and followed up to 22 yr. Serum obtained at the time of enrollment was assayed for ICAs, glutamic acid decarboxylase (GAD)65, insulin A (IA)-2 AA, and insulin AAs (IAAs). In FDRs who had ICAs in addition to GAD65 and IA-2 AAs, the cumulative risk of developing insulin-requiring diabetes was 80% at 6.7 yr of follow-up, whereas this risk in those with GAD65 and IA-2 AAs without ICAs was only 14% at 10 yr of follow-up (log rank: P < 0.00001). Cox regression analysis showed that diabetes risk was significantly associated with the presence of ICAs in both subjects with low titer and high titer GAD65 and IA-2 AAs. The addition of IAAs in GAD65 and IA-2 AA-positive relatives did not increase the cumulative risk for conversion to insulin-treated diabetes. We provide evidence that a subgroup of ICAs predicts a more rapid progression to insulin-requiring diabetes in GAD65 and IA-2 AA-positive relatives and should remain part of the assessment of T1DM risk for intervention trials. In addition, these findings provide impetus for efforts to identify a novel islet autoantigen(s) reactive with this ICA subset.
Collapse
Affiliation(s)
- Massimo Pietropaolo
- Division of Immunogenetics, Department of Pediatrics, Rangos Research Center, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. pietroma+@pitt.edu
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Abstract
The autoantibody assays that exist and that are being refined are of increasing importance to a broad spectrum of endocrine disorders. This is particularly true for type IA diabetes, which is one of the best-studied organ-specific autoimmune diseases. Autoantibodies are used as valuable markers in prediction and prevention studies of type IA diabetes. Autoantibodies related to other endocrine organs are also important because multiple related autoimmune endocrine and non-endocrine disorders are increased in frequency in patients and their families with autoimmunity. The availability of highly sensitive and specific autoantibody assays for the various endocrine disorders can allow physicians to better diagnose and promptly treat these conditions.
Collapse
Affiliation(s)
- Devasenan Devendra
- Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Box B140, Denver, CO 80262, USA
| | | | | |
Collapse
|
5
|
Zanone MM, Catalfamo E, Pietropaolo SL, Rabbone I, Sacchetti C, Cerutti F, Trucco M, Cavallo-Perin P. Glutamic acid decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual beta-cell function and glycemic control in young type 1 diabetic patients. Metabolism 2003; 52:25-9. [PMID: 12524658 DOI: 10.1053/meta.2003.50003] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Circulating autoantibodies (Ab) to islet autoantigens, glutamic acid decarboxylase (GAD(65)), and tyrosine phosphatase ICA512/IA-2 have been proposed as predictive markers of type 1 diabetes mellitus. To ascertain residual beta-cell function and the clinical relevance for monitoring autoimmunity after clinical manifestation of disease, we studied 63 children at diagnosis of type 1 diabetes (mean SD age 7.5 +/- 4 years) and 91 adolescent patients with type 1 diabetes (age 14.7 +/- 1.6 years) with a mean duration of disease of 7 +/- 3.5) years. Forty-two normal adolescent subjects (age 14.6 +/- 1.8 years) without a family history of diabetes were the control group. Anti-GAD(65) and ICA512/IA-2 Ab were assessed by a quantitative radioimmunoprecipitation assay. The relationship between humoral autoimmunity and clinical parameters was explored. GAD(65) and ICA512/IA-2 Ab were detected in 56% and 63% of newly diagnosed children and the prevalence was not different in relationship to clinical characteristics. Levels of GAD(65) Ab positively correlated with diagnosis age (P <.05). Both Ab were associated with islet cell antibodies (ICA) (P <.05), but one fifth of patients had at least 1 of the 2 Ab and absent ICA. At onset, only age showed a significant relationship to residual C-peptide secretion. Among the cohort of patients with diabetes of short-mid duration, GAD(65) and ICA512/IA-2 Ab were present in 44% and 45% of cases (P >.05 and P <.05 v newly diagnosed children, respectively) and more patients were identified by these Ab (68%) than by ICA alone (34%) (P <.05). In this cohort, levels of ICA512/IA-2 Ab negatively correlated with levels of glycosylated hemoglobin (HbA(1c)) (P <.005) and with daily insulin requirement (P <.05). Moreover, the presence of some residual C-peptide secretion was significantly associated with the presence of ICA512/IA-2 Ab (P <.05). Our findings confirm that positivity for either GAD(65) or ICA512/IA-2 Ab is a highly sensitive marker of type 1 diabetes in the pediatric age group, identifying a group of patients with absent ICA immunofluorescence. The persistence of Ab to islet tyrosine phosphatase possibly represents a marker of better glycemic control and less insulin requirement, indicating residual beta-cell function, thus conferring clinical and prognostic relevance to these Ab, as well as potential usefulness in intervention strategies.
Collapse
Affiliation(s)
- M M Zanone
- Division of Internal Medicine, University of Torino, Torino, Italy
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Horváth L, Cervenak L, Oroszlán M, Prohászka Z, Uray K, Hudecz F, Baranyi E, Madácsy L, Singh M, Romics L, Füst G, Pánczél P. Antibodies against different epitopes of heat-shock protein 60 in children with type 1 diabetes mellitus. Immunol Lett 2002; 80:155-62. [PMID: 11803047 DOI: 10.1016/s0165-2478(01)00336-4] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The aim of this study was to investigate the amounts and epitope specificity of antibodies against heat shock protein 60 (hsp60) in the sera of type 1 diabetic and healthy children. Antibodies specific for peptide p277 of human hsp60 and of M. bovis as well as for human hsp60, M. bovis hsp65 proteins were measured by ELISA. Other autoantibodies (islet cell antibodies, glutamate decarboxylase antibodies and IA-2 antibodies) were also determined. A total number of 83 serum samples from children with type 1 diabetes mellitus and 81 samples of control children were investigated. Epitope scanning of the hsp60 for linear antibody epitopes was carried out using synthetic peptides attached to pins. The antibody levels specific for peptide p277 of human- and of M. bovis origin were significantly (human: P=0.0002, M. bovis: P=0.0044) higher in the diabetic children group than in the healthy children. We could not find significant difference in the antibody levels to whole, recombinant hsp proteins among the examined groups of children. Antibodies to two epitope regions on hsp60 (AA394-413 and AA435-454) were detected in high titres in sera of children with diabetes mellitus. The first region similar to the sequence found in glutamate decarboxylase, whereas the second one overlaps with p277 epitope to a large extent. Presence of antibodies to certain epitopes of hsp60 (AA394-413-glutamic acid decarboxylase-like epitope; AA435-454-p277-like epitope) in diabetic children may reflect their possible role in the autoimmune diabetogenic process of the early diabetes.
Collapse
Affiliation(s)
- L Horváth
- Faculty of Medicine, 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4., H-1125, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
Pancreatic beta-cell mass (BCM) is a major determinant of the quantity of insulin that can be secreted. BCM is markedly reduced in type 1 diabetes because of selective autoimmune destruction of beta-cells. Accurate assessment of BCM in human diabetes is limited to autopsy studies, which usually suffer from inadequate clinical information; thus, the development of noninvasive means of BCM measurement could be important in intervention therapy. The goal of this study was to develop such noninvasive methods for measuring BCM featuring target-specific imaging probes and to investigate whether this technique is feasible, accurate, and predictive of BCM in normal and diabetic states. Using a beta-cell-specific monoclonal antibody IC2, modified with a radioisotope chelator for nuclear imaging, we showed that highly specific binding and accumulation to beta-cells occurs after intravenous administration of the probe, with virtually no binding to exocrine pancreas or stromal tissues. Furthermore, we observed a direct correlation between accumulation of the probe with BCM in diabetic and normal animals. Nuclear imaging of the animals that received an injection of the radioactive probe showed major difference in signal intensity between normal and diabetic pancreases. The results from this study set the route for further development of imaging probes for measuring BCM that would aid in diagnosis and treatment of diabetic patients in the clinic.
Collapse
Affiliation(s)
- A Moore
- Center for Molecular Imaging Research, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA.
| | | | | |
Collapse
|
8
|
Affiliation(s)
- D R Wegmann
- Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO 80262, USA
| | | |
Collapse
|
9
|
Abstract
Gangliosides in rat pancreatic tissue and isolated pancreatic islets were examined by methods including glycolipid-overlay techniques. The content of gangliosides in isolated pancreatic islets was approximately 6-fold higher than that in pancreatic tissue when compared on a protein basis. While N-glycolylneuraminic acid amounted to 7.2% of total lipid-bound sialic acids of pancreatic tissue, this molecular species was not detected in that of pancreatic islets. A remarkable difference in ganglioside composition was observed between pancreatic tissue and pancreatic islets. Pancreatic tissue showed a complex ganglioside pattern with GM3 as the largest ganglioside component, whereas isolated pancreatic islets had a simpler ganglioside profile without detectable amounts of GM3 and some other components. Pancreatic gangliosides were further examined by thin-layer chromatographic immunostaining with a monoclonal antibody A2B5 that reacts specifically with c-series gangliosides. Pancreatic tissue and pancreatic islets showed almost identical ganglioside patterns consisting of GT3, GT2, GQ1c, and GP1c. The concentration of c-series gangliosides in pancreatic islets was calculated to be more than 250-fold higher than that of pancreatic tissue. These results shows that pancreatic islet cells have a distinct ganglioside composition in rat pancreas.
Collapse
Affiliation(s)
- M Saito
- Department of Clinical Pharmacology and Therapeutics, University of Shizuoka, Shizuoka, Japan.
| | | |
Collapse
|
10
|
Morano S, Tiberti C, Cristina G, Sensi M, Cipriani R, Guidobaldi L, Torresi P, Medici F, Anastasi E, Di Mario U. Autoimmune markers and neurological complications in non-insulin-dependent diabetes mellitus. Hum Immunol 1999; 60:848-54. [PMID: 10527392 DOI: 10.1016/s0198-8859(99)00051-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To verify whether autoimmune markers related to nervous system structures and other autoimmunity indexes present in diabetes mellitus are associated with subclinical neuropathy, we examined 48 non-insulin-dependent diabetic patients with and without neuroelectrophysiological alterations. Nerve conduction velocity at the external sciatic-popliteal nerve, at the sural nerve, at the median and ulnar nerves level has been evaluated. Autoimmunity was investigated by evaluating glutamic acid decarboxylase (GAD-Ab), insulin (IAA), GM3, GD3 and GT1b gangliosides, pancreatic islet cell (IC-A) and anti-nervous-tissue autoantibody presence. Nerve conduction velocities were decreased in 72.9% of diabetic patients. Anti-insulin antibodies were detected in seven non-insulin created diabetic patients and in higher amount in subjects with (17.1%) than in those without (7.7%) asymptomatic neuropathy. Anti-GM3 antibodies were detected in four diabetic patients all of whom presented neurological complication. A significant correlation has been found between neurological damage and presence of anti-insulin antibodies (p<0.05). In the case of GM3 autoantibody, a similar result was obtained, but the data failed to reach statistical significance. Our data demonstrate that autoimmunity might play a role in the development of peripheral neuropathy.
Collapse
Affiliation(s)
- S Morano
- Department of Clinical Science, Endocrinology, Clinica Medica 2, La Sapienza University, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Saito M, Ito M, Sugiyama K. A specific loss of C-series gangliosides in pancreas of streptozotocin-induced diabetic rats. Life Sci 1999; 64:1803-10. [PMID: 10350354 DOI: 10.1016/s0024-3205(99)00122-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Gangliosides in pancreas, kidney, and liver tissues from streptozotocin-induced diabetic rats were analyzed by methods including thin-layer chromatographic (TLC) immunostaining with a specific monoclonal antibody to c-series gangliosides. In rats suffering diabetes for one month, the composition of major gangliosides in pancreatic tissue was almost identical to control, except for a slight increase in the content of GM3. Though c-series gangliosides such as GT3, GT2, GQ1c, and CP1c were expressed in normal pancreatic tissue, they were practically lost in pancreas of diabetic animals. A specific loss of c-series gangliosides was also observed in pancreatic tissue from rats suffering diabetes only for three days. While the composition of major gangliosides in the kidney did not change, streptozotocin-induced diabetic conditions brought about significant increases in contents of practically all major ganglioside species in liver tissue. No change was observed in the amount and composition of c-series gangliosides in both tissues. These results strongly suggest that c-series gangliosides are specifically localized in pancreatic B cells.
Collapse
Affiliation(s)
- M Saito
- Department of Clinical Pharmacology and Therapeutics, University of Shizuoka School of Pharmaceutical Sciences, Japan.
| | | | | |
Collapse
|
12
|
Murzenok P, Goranov V. Do local immune-neuroendocrine disturbances initiate diabetes? Can J Physiol Pharmacol 1999. [DOI: 10.1139/y99-012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
It has been suggested that there exists a local immune-neuroendocrine self-regulating system in the pancreas. The system consists of β-cells, nerve ganglia, intercellular fluid, connective tissue, and endothelial and immunocompetent cells. The local immune-neuroendocrine system governs the background level of insulin production by intrinsic mechanisms both in normal conditions and in a recovery period after different kinds of stress. The activity of this system by a complex of metabolic, environmental, nerve, and nonspecific immune factors has been determined. The local immune-neuroendocrine system is partially autonomous as a result of local integrative nerve circuits, morphological and functional substrates. Increased or decreased synthesis and release of some cytokines or biologically active substances (neurotransmitters, neuropeptides, γ-aminobutyric acid, metabolites, nitric oxide, ions, etc.) by various cell types in the local immune-neuroendocrine system above usual levels may result in disturbances of sensitivity and functions of β-cells. If the capability of the local immune-neuroendocrine system is insufficient for their compensation, the islet cell autoantigens may occur, the specific immune mechanisms are involved, and the pathological process becomes irreversible. Some ways for prevention of disturbances in the local immune-neuroendocrine system during the early and late phases of diabetes are presented.Key words: β-cells, diabetes, local immuneneuroendocrine system.
Collapse
|
13
|
Dotta F, Dionisi I, Farilla L, Di Mario U. The Use of Immunological Markers in IDDM After More Than 20 Years From ICA Description. ACTA ACUST UNITED AC 1998. [DOI: 10.1002/(sici)1099-0895(199607)12:2<121::aid-dmr159>3.0.co;2-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
14
|
Dotta F, Previti M, Neerman-Arbez M, Dionisi S, Cucinotta D, Lenti L, Di Mario U, Halban PA. The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not beta-cell specific. Endocrinology 1998; 139:316-9. [PMID: 9421429 DOI: 10.1210/endo.139.1.5708] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The pancreatic islet monosialo-ganglioside (GM2-1), an autoantigen in insulin-dependent diabetes mellitus (IDDM) recently shown to be the target of autoantibodies associated with diabetes development in relatives of IDDM patients, is islet specific within the pancreas, and its expression is metabolically regulatable. In the present study we sought to establish 1) whether GM2-1 is beta-cell specific, and 2) its intracellular localization. To this end, we analyzed the pattern of ganglioside expression in highly purified beta- and non-beta-cells isolated from rat islets. In addition, ganglioside levels were determined in subcellular fractions of a rat beta-cell line (INS). No qualitative or quantitative difference was found in the pattern of ganglioside expression between beta and non-beta rat islet cells, with GM3, GM2-1, and GD3 gangliosides expressed in both cell populations. Within INS cells, GM2-1 ganglioside was expressed in the fraction containing secretory granules and, to a lesser extent, in plasma membranes; GM3 was expressed in secretory granules, whereas GD3 was found only in plasma membranes. These data indicate that the GM2-1 autoantigen is not beta-cell specific within the islets, in accordance with the observation that this molecule is a target of islet cell autoantibodies that bind to the whole pancreatic islet. Interestingly, this autoantigen is present in secretory granules similarly to other autoantigens in IDDM (insulin, carboxypeptidase H, 38-kDa protein, etc.), suggesting that the autoimmunity to the components of this organelle may be central to the pathogenesis of the disease.
Collapse
Affiliation(s)
- F Dotta
- Department of Endocrinology, University of Rome La Sapienza, Italy
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Dotta F, Falorni A, Tiberti C, Dionisi S, Anastasi E, Torresi P, Lernmark A, Di Mario U. Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset. J Autoimmun 1997; 10:585-8. [PMID: 9451598 DOI: 10.1006/jaut.1997.0166] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The GM2-1 islet ganglioside has been sequenced, found to be a novel ganglioside structure with a sialic acid moiety in the terminal position and two residues of non-acetylated galactosamine and also shown to be a target of autoantibodies in a subset of ICA+ relatives of type 1 diabetic patients who subsequently progressed to the overt disease. In the present study we determined whether antibodies to GM2-1 or to other pancreatic gangliosides (a) are also expressed at disease onset and (b) are correlated with other diabetes-associated autoantibodies. Pancreatic gangliosides were extracted from human pancreas and purified by thin layer chromatography (TLC). Anti-ganglioside autoantibodies were determined using an indirect immunoperoxidase technique performed directly on TLC plates in the following groups of patients: (a) newly diagnosed type 1 diabetic subjects before insulin therapy (n = 45); all were tested for GAD65 autoantibodies in a fluid-phase RIA using 35S-methionine-labelled recombinant human GAD65. Of these patients, 24 were also tested for insulin autoantibodies (IAA) by a competitive fluid phase radioimmunoassay and 21 were tested for GAD67 reactivity. (b) Forty-two age- and sex-matched normal control subjects. Autoantibodies to GM2-1, but not to other pancreatic gangliosides (GM3, GD3, GD1a), were expressed in 31 of 45 new-onset type 1 diabetic subjects and in one of 42 normal controls (P < 0.01), while anti-GAD65, IAA and anti-GAD67 were found in 31 of 45, 12 of 24 and three of 21 patients respectively, but not in the control group of subjects. Interestingly, occurrence of GM2-1 autoantibodies was significantly correlated (P < 0.005) with positivity for GAD65 autoantibodies, but not for IAA or GAD67 autoantibodies. It is of note that both GAD and gangliosides are mainly expressed in islets and in neuronal tissues and, therefore, type 1 diabetes may be regarded as a neuroendocrine autoimmune disease.
Collapse
Affiliation(s)
- F Dotta
- Department of Endocrinology, University La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Tiberti C, Falorni A, Torresi P, Vecci E, Anastasi E, Dotta F, Di Mario U. A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. J Immunol Methods 1997; 207:107-13. [PMID: 9368637 DOI: 10.1016/s0022-1759(97)00101-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This paper describes a simple, rapid, routine method to detect anti-GAD65 autoantibodies by a solid-phase radioimmunoassay using human recombinant GAD65 coated microwells and 125I-protein A to reveal antibody binding. Both recombinant and radiolabelled proteins are commercially available. This new method was validated by investigating the presence of GAD65 autoantibodies in two different studies (A and B); the first including subjects originating from our own case histories (group A sera), the second made up of recoded subjects and standards sent to our lab by the Second International GAD Antibody Workshop organizers (group B sera). In study A we tested sera from 52 normal subjects, 25 newly diagnosed type 1 diabetics and 3 stiff man syndrome (SMS) subjects detecting GAD65 autoantibodies in 72% of IDDM and 100% of SMS patients. In study B we tested (in blind fashion) 89 recoded sample sera or standards that were part of the larger group used in the Second International GAD Antibody Workshop, finding GAD65 autoantibodies in 3.3% of healthy control subjects (1/30), 60% of IDDM patients (18/30), 100% of ICA + nondiabetic subjects (3/3) but in none of 4 nondiabetic patients with Graves disease. Comparing our solid-phase RIA results with those published for the same sera from the Second International GAD Antibody Workshop we obtained for our method a sensitivity of 85.7%, a specificity of 93.9% and a consistency of 100%. These result indicate that our assay, which is based on commercially available reagents, should be a useful tool for the detection of GAD65 autoantibodies in large scale studies.
Collapse
Affiliation(s)
- C Tiberti
- Department of Endocrinology, La Sapienza University, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
17
|
Slover RH, Eisenbarth GS. Prevention of type I diabetes and recurrent beta-cell destruction of transplanted islets. Endocr Rev 1997; 18:241-58. [PMID: 9101139 DOI: 10.1210/edrv.18.2.0299] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- R H Slover
- Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver 80262, USA
| | | |
Collapse
|
18
|
Wegmann DR. The immune response to islets in experimental diabetes and insulin-dependent diabetes mellitus. Curr Opin Immunol 1996; 8:860-4. [PMID: 8994867 DOI: 10.1016/s0952-7915(96)80016-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Over the past year, a number of important observations have been made in the nonobese diabetic mouse and in clinical insulin-dependent diabetes mellitus concerning the autoimmune response to islets. Assays have advanced to the point where individuals at risk for insulin-dependent diabetes mellitus can be readily identified prior to the onset of symptoms and a number of peptides of proteins expressed by the beta cell have been shown to protect nonobese diabetic mice from developing diabetes. The contributions of CD4+ and CD8+ T cells to beta cell destruction are beginning to be understood and this information will probably be of value in the design of intervention strategies for use in human subjects.
Collapse
Affiliation(s)
- D R Wegmann
- Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver 80262, USA
| |
Collapse
|
19
|
Abstract
Type 1 diabetes mellitus (IDDM) is a disease caused by the autoimmune destruction of insulin-producing pancreatic beta cells that takes place in genetically predisposed individuals. The results of the studies performed so far during the search for "the target antigen" in beta cell autoimmunity have indicated that, unlike many autoimmune disorders, type 1 diabetes appears to be the result of an autoimmune response to a multiplicity of autoantigens. Autoantibodies and autoreactive T lymphocytes reacting with islet target molecules of protein or glycolipid nature have been shown in the circulation of individuals and of animal models of type 1 diabetes (NOD mouse and BB rat) before and at the onset of the disease. In the present article we have reviewed the data available on the antigenic determinants in type 1 diabetes, with particular reference to those recognized by autoantibodies which represent the best available predictive marker of future disease development in large scale screening studies.
Collapse
Affiliation(s)
- F Dotta
- Clinica Medica 2-Endocrinologia, University of Rome La Sapienza, Italy
| | | |
Collapse
|
20
|
Affiliation(s)
- M R Christie
- Department of Medicine, King's College School of Medicine and Dentistry, London, UK
| |
Collapse
|